A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease

Current Alzheimer Research

Volumn 11, Issue 5, 2014, Pages 413-421

  Schwam, Elias M ^a   Nicholas, Timothy ^a   Chew, Robert ^a   Billing Jr , Clare B ^a   Davidson, Wendy ^a   Ambrose, Darlene ^b   Altstiel, Larry D ^a  

^a PFIZER INC   (United States)

^b Execupharm Inc   (United States)

Author keywords

Alzheimer's disease; PF 04447943; Phosphodiesterase 9 inhibitor

Indexed keywords

PF 04447943; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE 9A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; 6-(4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL)-1-(TETRAHYDRO-2H-PYRAN-4-YL)-1,5-DIHYDRO-4H-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE; PYRAZOLE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN HEMATOMA; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; INCIDENCE; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NAUSEA; NEUROPSYCHIATRIC INVENTORY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STOMACH CANCER; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHODIESTERASE INHIBITORS; PYRAZOLES; PYRIMIDINONES; TREATMENT OUTCOME;

EID: 84904041713     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140505100858     Document Type: Article

References (24)

1. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273: 15559-155564 (1998).
2. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharm 59(6): 367-374 (2010).
3. Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF, et al. Phosphodiesterase9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharm Exp Ther 341: 396-409 (2012).
4. Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, et al. Identification of a brain penetrant PDE9Ainhibitor utilizing prospective design and chemical enablement as a rapid leadoptimization strategy. J Med Chem 52: 7946-7949 (2009).
5. Schmidt CJ. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr Topics Med Chem 10: 222-230 (2010).
6. Nicholas T, Evans R, Styren S, Qui R, Wang EQ, Nelson F, et al. PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinalfluid: Translation from non-clinical species to healthy human volunteers. Alzheimers Dementia 5(4): P330 (2009).
7. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1, 5-dihydro-4H-pyrazolo[3, 4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 61: 665-676 (2011).
8. Vardigan JD, Converso A, Hutson PH, Uslaner JM. The selective phosphodiesterase 9 inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J Neurogenetics 25(4): 120-126 (2011).
9. Kleiman RJ, Lanz TA, Finley, JE, Bove SE, Majchrzak MJ, Becker SL, et al. Dendritic spine density deficits in the hippocampal CA1 region of young Tg2576 mice are ameliorated with the PDE9A inhibitor PF-04447943. Alzheimers Dementia 6(4): S563 (2010).
10. Bonkdale WL, Winblad B, Ravid R, Cowburn RF. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci Letters 187: 5-8 (1995).
11. Baltrons MA, Pifarre P, Ferrer, Carot JM, Garcia A. Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Crutzfeldt-Jakob disease, and multiple sclerosis brains. Neurobiol Dis 17: 462-472 (2004).
12. Reyes-Irisarri E, Markerick-Van Ittersum M, Mengod G, de Vente J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur J Neurosci 25: 3332-3338 (2007).
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV); Washington DC (1994).
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7): 939-944 (1984).
15. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-198 (1975).
16. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7: 486-488 (1980).
17. Evans R, Nicholas T, Le V, Qiu R, Martin W, Martin D, et al. Safety and pharmacokinetics of PF-04447943, a PDE9A inhibitor, in single and multiple dose Phase 1 studies in healthy volunteers. Alzheimers Dementia 6(4): S135 (2010).
18. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 14(11): 1356-1364 (1984).
19. Cummings JL, Mega M, Grya K. Rosenberg-Thompson S, CarusiDA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12): 2308-2314 (1994).
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, U. S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH (1976).
21. Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Suicidality issues in clinical trials: Columbia Suicide Severity Rating Scale (C-SSRS). Available at: www. fda. gov.
22. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzhiemer disease. Arch Intern Med 158: 1021-1031 (1998).
23. Savonenko AV, Melnikova T, Hiatt A, Li T, Worley PF, TroncosoJC, et al. Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharm Rev 37: 261-277 (2012).
24. Itzecka J. Decreased cerebrospinal fluid cGMP levels in patients with amyotrophic lateral sclerosis. J Neural Transm 111: 167-172 (2004).